Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain
Aims: To develop an effective universal vaccine against antigenically different influenza viruses. Materials & methods: We generated influenza virus-like particles (VLPs) expressing the H1 and H3 antigens with or without M2e5x. VLP-induced immune responses and crossprotection against H1N1, H3N2 or H5N1 viruses were assessed to evaluate their protective efficacy. Results: H1H3M2e5x immunization elicited higher crossreactive IgG antibodies than H1H3 VLPs. Upon challenge, both VLPs enhanced lung IgG, IgA and germinal center B-cell responses compared with control. While these VLPs conferred protection, H1H3M2e5x showed greater lung viral load reduction than H1H3 VLPs with minimal body weight loss. Conclusion: Utilizing VLPs containing dual-hemagglutinin, along with M2e5x, can be a vaccination strategy for inducing crossprotection against influenza A viruses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 19(2024), 9 vom: 22. Apr., Seite 741-754 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mao, Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hemagglutinin |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2023-0353 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368806715 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368806715 | ||
| 003 | DE-627 | ||
| 005 | 20240422232133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2023-0353 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1383.xml |
| 035 | |a (DE-627)NLM368806715 | ||
| 035 | |a (NLM)38390688 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mao, Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aims: To develop an effective universal vaccine against antigenically different influenza viruses. Materials & methods: We generated influenza virus-like particles (VLPs) expressing the H1 and H3 antigens with or without M2e5x. VLP-induced immune responses and crossprotection against H1N1, H3N2 or H5N1 viruses were assessed to evaluate their protective efficacy. Results: H1H3M2e5x immunization elicited higher crossreactive IgG antibodies than H1H3 VLPs. Upon challenge, both VLPs enhanced lung IgG, IgA and germinal center B-cell responses compared with control. While these VLPs conferred protection, H1H3M2e5x showed greater lung viral load reduction than H1H3 VLPs with minimal body weight loss. Conclusion: Utilizing VLPs containing dual-hemagglutinin, along with M2e5x, can be a vaccination strategy for inducing crossprotection against influenza A viruses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a M2e5x | |
| 650 | 4 | |a hemagglutinin | |
| 650 | 4 | |a influenza virus | |
| 650 | 4 | |a universal vaccine | |
| 650 | 4 | |a virus-like particles | |
| 650 | 7 | |a Hemagglutinins |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Eom, Gi-Deok |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Keon-Woong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min-Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Ki-Back |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Hae-Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Quan, Fu-Shi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 19(2024), 9 vom: 22. Apr., Seite 741-754 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:9 |g day:22 |g month:04 |g pages:741-754 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2023-0353 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 9 |b 22 |c 04 |h 741-754 | ||